Recent News

• 10.28.2025 - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
• 10.20.2025 - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
• 10.13.2025 - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
• 10.09.2025 - Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Recent Filings

• 10.22.2025 - 8-K Current report
• 10.20.2025 - 8-K Current report
• 10.17.2025 - PRE 14A Other preliminary proxy statements
• 10.16.2025 - 8-K Current report
• 10.09.2025 - 8-K Current report
• 10.09.2025 - EX-99.1 EX-99.1
• 10.09.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.09.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.08.2025 - 4 Statement of changes in beneficial ownership of securities